Under the terms of the multi-year agreement, Resilience will produce mRNA for the COVID-19 vaccine at its facility in Mississauga, Ontario in Canada
Moderna has announced an agreement with biopharmaceuticals manufacturer National Resilience to manufacture drug substance for the Moderna COVID-19 vaccine.
Under the terms of the multi-year agreement, Resilience will produce mRNA for the COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide.
“Moderna’s COVID-19 vaccine has saved countless lives, and we’re excited to manufacture mRNA for this important vaccine,” said Rahul Singhvi, Sc.D, CEO of Resilience. “This collaboration has the potential to ensure more people are protected around the world from the deadly COVID-19 virus.”
Moderna recently announced a collaboration to bring mRNA manufacturing to Canada through a Memorandum of Understanding (MoU) with the government of Canada to build a messenger RNA (mRNA) vaccine manufacturing facility in the country including access to Moderna’s mRNA development engine. The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities.